Table 1.
Patient characteristics, information on B-cell lymphoma, initial laboratory results, and initial information related to SARS-CoV-2
| Factor | Value |
|---|---|
| Age, years, (range) | 68 (56–79) |
| Male sex, n (%) | 23 (52.3) |
| Information on B-cell lymphoma | |
| Period since diagnosis of B-cell lymphoma to SARS-CoV-2 onset, months, (range) | 27 (14–83) |
| Period since last treatment for B-cell lymphoma to SARS-COV-2 onset, months, (range) | 3.5 (1–15) |
| Subtype of B-cell lymphomas, n (%) | |
| Follicular lymphoma | 20 (45.5) |
| Diffuse large B-cell lymphoma | 17 (38.6) |
| Lymphoplasmacytic lymphoma | 2 (4.5) |
| Mucosa-associated lymphoid tissue lymphoma | 2 (4.5) |
| Mantle cell lymphoma | 1 (2.3) |
| B-lymphoblastic lymphoma | 1 (2.3) |
| Other B-cell non-Hodgkin lymphoma | 1 (2.3) |
| Number of patients using anti-CD20 medication, n (%) | |
| Rituximab | 35 (79.5) |
| Obinutuzumab | 19 (43.2) |
| Number of patients using other medication for lymphoma, n (%) | |
| Bendamustine | 26 (59.1) |
| Polatuzumab vedotin | 9 (20.5) |
| Within 1 year of last treatment for B-cell lymphoma, n (%) | 31 (70.5) |
| Multiple treatment lines, n (%) | 13 (29.5) |
| Initial laboratory results | |
| Absolute lymphocyte count, cells/mL, (range) | 482 (268–800) |
| Absolute neutrophil count, cells/mL, (range) | 2592 (1550–4072) |
| Platelet count, cells/mL, (range) | 166,000 (78,000–198000) |
| Hemoglobin, g/dL, (range) | 11.9 (9.6–13.7) |
| C-reactive protein, mg/dL, (range) | 2.8 (0.9–9.3) |
| Lactate dehydrogenase, U/L, (range) | 274 (190–366) |
| Interleukin-6, pg/mL, (range) | 27.2 (8.3–68.7) |
| Initial information related to SARS-CoV-2 | |
| ≥ 3 COVID-19 vaccinations, n (%) | 29 (65.9) |
| Period since onset of COVID-19 to admission to our hospital, days, (range) | 5.5 (1.75–14.25) |
| Transferred from another hospital with a diagnosis of persistent infection, n (%) | 6 (13.6) |
| Positive spike-specific antibody, n (%) | 33 (75.0) |
| Positive nucleocapsid protein antibody, n (%) | 3 (6.8) |
| Viral load, copies/µL, (range) | 68,026 (3704–1016644) |
| CT findings suggestive of COVID-19 pneumonia | 28 (63.6) |
| Sublineages of omicron variant, n (%) | |
| BA.1 | 5 (11.4) |
| BA.2 (including FR) | 11 (25.0) |
| BA.5 (including BF and BU) | 18 (40.9) |
| XBB (including EG) | 7 (15.9) |
| BA.2.86 | 1 (2.3) |
| Not assessed | 2 (4.5) |